These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
588 related articles for article (PubMed ID: 9626234)
21. Long-term follow-up of survival in Hodgkin's lymphoma. Canellos GP; Niedzwiecki D; Johnson JL N Engl J Med; 2009 Dec; 361(24):2390-1. PubMed ID: 20007568 [No Abstract] [Full Text] [Related]
22. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma]. Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685 [TBL] [Abstract][Full Text] [Related]
24. Drug selection in the treatment of Hodgkin's disease. Bonadonna G; Santoro A Hematol Oncol; 1983; 1(1):3-12. PubMed ID: 6203820 [No Abstract] [Full Text] [Related]
25. Hodgkin lymphoma: MOPP chemotherapy to PD-1 blockade and beyond. Ansell SM Am J Hematol; 2016 Jan; 91(1):109-12. PubMed ID: 26505486 [TBL] [Abstract][Full Text] [Related]
26. [Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma]. Zhen ZJ; Sun XF; Xia Y; Wang ZH; Ling JY Ai Zheng; 2006 Apr; 25(4):471-5. PubMed ID: 16613683 [TBL] [Abstract][Full Text] [Related]
27. Early intensification treatment approach in advanced-stage Hodgkin lymphoma. Borchmann P Hematol Oncol Clin North Am; 2014 Feb; 28(1):65-74. PubMed ID: 24287068 [TBL] [Abstract][Full Text] [Related]
29. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. Chronowski GM; Wilder RB; Tucker SL; Ha CS; Sarris AH; Hagemeister FB; Barista I; Hess MA; Cabanillas F; Cox JD Cancer; 2002 Dec; 95(12):2534-8. PubMed ID: 12467067 [TBL] [Abstract][Full Text] [Related]
30. ABVD treatment of MOPP failures in Hodgkin's disease: a re-examination of goals of salvage therapy. Clamon GH; Corder MP Cancer Treat Rep; 1978 Mar; 62(3):363-7. PubMed ID: 77188 [No Abstract] [Full Text] [Related]
31. [Diffuse thymus hyperplasia following chemotherapy for nodular sclerosing Hodgkin lymphoma]. Hermann R; Greminger P; Dommann-Scherrer C; Krestin GP; Stahel R Schweiz Med Wochenschr; 1994 Sep; 124(38):1666-71. PubMed ID: 7524146 [TBL] [Abstract][Full Text] [Related]
32. Hodgkin's disease: controversies and challenges for the future. Tura S; Canellos G; Goldstone A; Longo D; McMillan A; Urba W; Zinzani PL Haematologica; 1991; 76(4):263-79. PubMed ID: 1724436 [No Abstract] [Full Text] [Related]
33. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors. Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496 [TBL] [Abstract][Full Text] [Related]
34. Is ABVD the standard regimen for Hodgkin's disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD? Canellos GP Leukemia; 1996 Jun; 10 Suppl 2():s68. PubMed ID: 8649055 [No Abstract] [Full Text] [Related]
35. Combined chemotherapy (MOPP or ABVD)-radiotherapy approach in advanced Hodgkin's disease. Bonadonna G; Zucali R; De Lena M; Valagussa P Cancer Treat Rep; 1977 Aug; 61(5):769-77. PubMed ID: 70270 [No Abstract] [Full Text] [Related]
36. Treatment of childhood Hodgkin's disease without radiotherapy. van den Berg H; Zsiros J; Behrendt H Ann Oncol; 1997; 8 Suppl 1():15-7. PubMed ID: 9187423 [TBL] [Abstract][Full Text] [Related]
37. Vancouver hybrid: preliminary experience in the treatment of Hodgkin's disease in childhood and adolescence. Khan SP; Gilchrist GS; Arndt CA; Smithson WA; Chen MG; Schomberg PJ; Matsumoto JM; O'Fallon WM Mayo Clin Proc; 1994 Oct; 69(10):949-54. PubMed ID: 7523802 [TBL] [Abstract][Full Text] [Related]
38. Impact of lymphoma treatments on spermatogenesis and sperm deoxyribonucleic acid: a multicenter prospective study from the CECOS network. Bujan L; Walschaerts M; Brugnon F; Daudin M; Berthaut I; Auger J; Saias J; Szerman E; Moinard N; Rives N; Hennebicq S Fertil Steril; 2014 Sep; 102(3):667-674.e3. PubMed ID: 25044088 [TBL] [Abstract][Full Text] [Related]
39. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Federico M; Luminari S; Iannitto E; Polimeno G; Marcheselli L; Montanini A; La Sala A; Merli F; Stelitano C; Pozzi S; Scalone R; Di Renzo N; Musto P; Baldini L; Cervetti G; Angrilli F; Mazza P; Brugiatelli M; Gobbi PG; J Clin Oncol; 2009 Feb; 27(5):805-11. PubMed ID: 19124807 [TBL] [Abstract][Full Text] [Related]
40. Hodgkin's disease and the risk of acute leukemia in successfully treated patients. Valagussa P; Bonadonna G Haematologica; 1998 Sep; 83(9):769-70. PubMed ID: 9825571 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]